Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.
Christian W KellerTobias RuckDonal McHughSteffen PfeufferCatharina C GrossCatharina KorsukewitzNico MelzerLuisa KlotzSven G MeuthChristian MünzFalk NimmerjahnHeinz WiendlJan D LünemannPublished in: Annals of clinical and translational neurology (2019)
Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell-depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high-affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing-remitting multiple sclerosis. No differences in clinical and MRI-based efficacy parameters, the development of severe infusion-associated reactions and secondary autoimmune diseases during a 2 year follow-up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.
Keyphrases
- multiple sclerosis
- white matter
- end stage renal disease
- copy number
- ejection fraction
- newly diagnosed
- magnetic resonance imaging
- peritoneal dialysis
- cell therapy
- prognostic factors
- low dose
- genome wide
- single cell
- rheumatoid arthritis
- early onset
- gene expression
- diffuse large b cell lymphoma
- magnetic resonance
- computed tomography
- stem cells
- disease activity
- drug induced
- smoking cessation